Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program initiated on February 6, 2024. As part of a larger 12-month buyback plan worth up to DKK 20 billion, the company has been actively purchasing B shares. From February 6 to April 30, 2024, Novo Nordisk is set to repurchase shares amounting to DKK 2.1 billion. Recent transactions, as of April 12, 2024, show that the company has acquired 1,926,500 B shares at an average price of DKK 864.79 each, totaling DKK 1,666,024,627. These transactions have increased Novo Nordisk's treasury shares to 48,467,207 B shares, which is 1.1% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people worldwide.

Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program initiated on February 6, 2024. As part of a larger 12-month buyback plan worth up to DKK 20 billion, the company has been actively purchasing B shares. From February 6 to April 30, 2024, Novo Nordisk is set to repurchase shares amounting to DKK 2.1 billion. Recent transactions, as of April 12, 2024, show that the company has acquired 1,926,500 B shares at an average price of DKK 864.79 each, totaling DKK 1,666,024,627. These transactions have increased Novo Nordisk's treasury shares to 48,467,207 B shares, which is 1.1% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people worldwide.